Recordati SpA (MIL:REC) Beneish M-Score: -2.49 (As of Jun. 24, 2026)


MIL:REC Recordati SpA MIL:REC
96 GF Score
Price €51.55
GF Value €60.63
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Recordati SpA Beneish M-Score?

Recordati SpA MIL:REC +0.88% 96 Beneish M-Score is -2.49 as of Jun. 24, 2026. GuruFocus rates MIL:REC with a GF Score™ of 96/100 and a GF Value™ of €60.63 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 911 Drug Manufacturers companies, Recordati SpA ranks worse than 50.82% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.49 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Recordati SpA's Beneish M-Score or its related term are showing as below:

MIL:REC' s Beneish M-Score Range Over the Past 10 Years
Min: -2.77   Med: -2.47   Max: -2.19
Current: -2.49

During the past 13 years, the highest Beneish M-Score of Recordati SpA was -2.19. The lowest was -2.77. And the median was -2.47.


Recordati SpA Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Recordati SpA's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Recordati SpA Beneish M-Score Chart

Recordati SpA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.55 -2.51 -2.35 -2.50 -2.56

Recordati SpA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.47 -2.42 -2.35 -2.56 -2.49

MIL:REC vs LLY, JNJ, ABBV: Beneish M-Score Comparison

For the Drug Manufacturers - General subindustry, Recordati SpA's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Recordati SpA Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Recordati SpA's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Recordati SpA's Beneish M-Score falls into.


MIL:REC
96GF Score
Recordati SpA MIL:REC
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recordati SpA Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Recordati SpA for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9854+0.528 * 0.9815+0.404 * 0.9629+0.892 * 1.0987+0.115 * 0.9799
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9893+4.679 * -0.011872-0.327 * 0.9971
=-2.49

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €765 Mil.
Revenue was 713.424 + 662.22 + 632.321 + 643.882 = €2,652 Mil.
Gross Profit was 510.826 + 472.649 + 432.408 + 423.85 = €1,840 Mil.
Total Current Assets was €1,728 Mil.
Total Assets was €5,335 Mil.
Property, Plant and Equipment(Net PPE) was €229 Mil.
Depreciation, Depletion and Amortization(DDA) was €208 Mil.
Selling, General, & Admin. Expense(SGA) was €738 Mil.
Total Current Liabilities was €1,368 Mil.
Long-Term Debt & Capital Lease Obligation was €1,757 Mil.
Net Income was 153.061 + 117.338 + 110.165 + 91.08 = €472 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0 Mil.
Cash Flow from Operations was 102.87 + 172.568 + 152.157 + 107.383 = €535 Mil.
Total Receivables was €706 Mil.
Revenue was 679.96 + 598.478 + 557.414 + 577.847 = €2,414 Mil.
Gross Profit was 458.772 + 413.362 + 385.124 + 386.226 = €1,643 Mil.
Total Current Assets was €1,566 Mil.
Total Assets was €5,166 Mil.
Property, Plant and Equipment(Net PPE) was €204 Mil.
Depreciation, Depletion and Amortization(DDA) was €178 Mil.
Selling, General, & Admin. Expense(SGA) was €679 Mil.
Total Current Liabilities was €986 Mil.
Long-Term Debt & Capital Lease Obligation was €2,049 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(764.728 / 2651.847) / (706.335 / 2413.699)
=0.288376 / 0.292636
=0.9854

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(1643.484 / 2413.699) / (1839.733 / 2651.847)
=0.680898 / 0.693755
=0.9815

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (1728.186 + 229.165) / 5334.541) / (1 - (1565.88 + 203.758) / 5166.142)
=0.63308 / 0.657455
=0.9629

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=2651.847 / 2413.699
=1.0987

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(177.958 / (177.958 + 203.758)) / (207.975 / (207.975 + 229.165))
=0.466205 / 0.475763
=0.9799

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(738.359 / 2651.847) / (679.301 / 2413.699)
=0.278432 / 0.281436
=0.9893

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1757.101 + 1368.191) / 5334.541) / ((2049.423 + 985.996) / 5166.142)
=0.58586 / 0.58756
=0.9971

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(471.644 - 0 - 534.978) / 5334.541
=-0.011872

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Recordati SpA has a M-score of -2.49 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.49 mean?
Recordati SpA (MIL:REC) has a Beneish M-Score of -2.49 as of Jun. 24, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Recordati SpA and its competitors. According to the industry distribution chart, Recordati SpA ranks #463 out of 911 companies in the Drug Manufacturers industry, placing it in the top 50.8%.
Is Recordati SpA's Beneish M-Score too high?
Recordati SpA's current Beneish M-Score is -2.49. Based on the distribution chart, Recordati SpA ranks #463 out of 911 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Recordati SpA has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Recordati SpA's Beneish M-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Recordati SpA ranks #463 out of 911 companies for Beneish M-Score. This places Recordati SpA in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Recordati SpA and its competitors. Recordati SpA's current Beneish M-Score is -2.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Recordati SpA stock overvalued right now?
Based on GuruFocus' analysis, Recordati SpA (MIL:REC) is currently considered Modestly Undervalued. The stock's GF Value™ is €60.63, compared to a current price of €51.55 — trading 15% below its estimated fair value. The current Beneish M-Score is -2.49. Recordati SpA's overall GF Score™ is 96/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Recordati SpA (MIL:REC), the current Beneish M-Score is -2.49 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Recordati SpA (MIL:REC) Overvalued in 2026?

Based on GuruFocus' analysis, Recordati SpA stock appears to be undervalued. The current stock price of €51.55 is trading 15% below its estimated GF Value™ of €60.63. GuruFocus considers Recordati SpA to be Modestly Undervalued.

Key valuation signals for MIL:REC:

  • Beneish M-Score: -2.49
  • GF Value™: €60.63 vs. price of €51.55 (15% below fair value)
  • GF Score™: 96/100 with 3 warning signs

No single metric tells the full story. See the MIL:REC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Recordati SpA Business Description

Address Via Matteo Civitali 1, MIlan, ITA, 20148
Recordati SpA is engaged in the development, production, and marketing of pharmaceutical products or of pharmaceutical chemicals. The Company operates in a broad and diverse context, which includes general medicine, specialist medicine, self-medication, and rare diseases. In addition, it is also active in the field of urology, with treatments for benign prostatic hyperplasia and male functional disorders, and in psychiatry. The Company's only operating segment is the Specialty & Primary Care segment. Its geographic areas are Europe, Australasia, America, and Africa.
96GF Score

Get the complete analysis for MIL:REC

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€51.55
Price
€60.63
GF Value